New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 24, 2013
17:22 EDTCORTCorcept Therapeutics enters services agreement with Centric Health
Corcept Therapeutics disclosed in a regulatory filing that on May 21, the company entered into a services agreement with Centric Health Resources to provide the exclusive specialty pharmacy and patient services program for the company's drug Korlym, starting early in Q3. Under the terms of the agreement, subject to certain exceptions, Centric will act as the exclusive specialty pharmacy distributor of the product in the United States for the term of the agreement. The initial term of the agreement is a period of three years from the initiation of services under the agreement.
News For CORT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 13, 2015
19:35 EDTCORTCorcept announces results of Phase 1/2 mifepristone/eribulin study
Corcept Therapeutics, a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, announced results of a multi-center Phase 1/2 dose-escalation study of mifepristone and chemotherapy drug eribulin, or Halaven, that show it is well tolerated and clinically active in patients with triple-negative breast cancer. These results were published in the 2015 American Society of Clinical Oncology, ASCO, Annual Meeting Program. Corcept CEO Joseph Belanoff said. "If our Phase 1/2 demonstrates efficacy, we plan to begin a Phase 3 study in early 2016. We are also developing compounds from our portfolio of next-generation selective GR antagonists. We hope to advance our lead compound, CORT125134, to a Phase 2 study for the treatment of a second oncology indication early next year."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use